{{Drugbox
| IUPAC_name = ''N''-[(1''S'')-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1''H''-indazole-3-carboxamide
| image = AB-PINACA_structure-rev1.png

<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = Schedule I<!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_DE = Anlage II
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1445752-09-9
| ATC_prefix =
| ATC_suffix =
| PubChem = 71301472
|  ChemSpiderID = 28537615
|  smiles = CCCCCn1c2ccccc2c(n1)C(=O)N[C@@H](C(C)C)C(=O)N
|  StdInChI = 1S/C18H26N4O2/c1-4-5-8-11-22-14-10-7-6-9-13(14)16(21-22)18(24)20-15(12(2)3)17(19)23/h6-7,9-10,12,15H,4-5,8,11H2,1-3H3,(H2,19,23)(H,20,24)/t15-/m0/s1
|  StdInChIKey = GIMHPAQOAAZSHS-HNNXBMFYSA-N
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6J3KC3S2PA

<!--Chemical data-->
| C=18 | H=26 | N=4 | O=2
| molecular_weight = 330.43 g/mol
}}

'''AB-PINACA''' is a compound that was first identified as a component of [[synthetic cannabis]] products in Japan in 2012.<ref>{{Cite journal | last1 = Uchiyama | first1 = N. | last2 = Matsuda | first2 = S. | last3 = Wakana | first3 = D. | last4 = Kikura-Hanajiri | first4 = R. | last5 = Goda | first5 = Y. | title = New cannabimimetic indazole derivatives, ''N''-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1''H''-indazole-3-carboxamide (AB-PINACA) and ''N''-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1''H''-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products | doi = 10.1007/s11419-012-0171-4 | journal = Forensic Toxicology | volume = 31 | pages = 93–100 | year = 2012 | pmid =  | pmc = }}</ref>

It was originally developed by [[Pfizer]] in 2009 as an [[analgesic]] medication.<ref>{{cite web | url=https://www.caymanchem.com/app/template/Product.vm/catalog/14038 | title=AB-PINACA| publisher=Cayman Chemical | accessdate=25 June 2015}}</ref><ref>{{cite journal | url=https://www.google.com/patents/WO2009106980A3 | title=Patent WO/2009/106980 - Indazole derivatives}}</ref>

AB-PINACA acts as a potent [[agonist]] for the [[CB1 receptor|CB<sub>1</sub> receptor]] (''K''<sub>i</sub>&nbsp;=&nbsp;2.87&nbsp;nM, [[EC50|EC<sub>50</sub>]]&nbsp;=&nbsp;1.2&nbsp;nM) and [[CB2 receptor|CB<sub>2</sub> receptor]] (''K''<sub>i</sub>&nbsp;=&nbsp;0.88&nbsp;nM, EC<sub>50</sub>&nbsp;=&nbsp;2.5&nbsp;nM) and fully substitutes for [[Tetrahydrocannabinol|Δ<sup>9</sup>-THC]] in rat discrimination studies, while being 1.5x more potent.<ref>{{cite journal|doi=10.1021/acschemneuro.5b00112|pmid=26134475|title=Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA|journal=ACS Chemical Neuroscience|volume=6|issue=9|pages=1546–59|year=2015|last1=Banister|first1=Samuel D.|last2=Moir|first2=Michael|last3=Stuart|first3=Jordyn|last4=Kevin|first4=Richard C.|last5=Wood|first5=Katie E.|last6=Longworth|first6=Mitchell|last7=Wilkinson|first7=Shane M.|last8=Beinat|first8=Corinne|last9=Buchanan|first9=Alexandra S.|last10=Glass|first10=Michelle|last11=Connor|first11=Mark|last12=McGregor|first12=Iain S.|last13=Kassiou|first13=Michael}}</ref><ref>{{cite journal | url=http://jpet.aspetjournals.org/content/early/2015/06/23/jpet.115.225326.short | title=AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ<sup>9</sup>-Tetrahydrocannabinol-Like Effects in Mice |author1=Jenny L Wiley |author2=Julie A Marusich |author3=Timothy W Lefever |author4=Kateland R Antonazzo |author5=Michael T Wallgren |author6=Ricardo A Cortes |author7=Purvi R Patel |author8=Megan Grabenauer |author9=Katherine N Moore |author10=Brian F Thomas | journal=Journal of Pharmacology and Experimental Therapeutics | volume=354 | issue=3 | pages=328–39 |date=June 2015  | doi=10.1124/jpet.115.225326 | pmid=26105953| pmc=4538877 }}</ref>

==Side effects==

There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.<ref>{{cite journal | url=http://www.nejm.org/doi/full/10.1056/NEJMp1505328 | title=Synthetic Cannabinoid–Related Illnesses and Deaths |author1=Jordan Trecki |author2=Roy R. Gerona |author3=Michael D. Schwartz | journal=New England Journal of Medicine |date=July 2015  | volume=373 | issue=2 | pages=103–107 | doi=10.1056/NEJMp1505328 | pmid=26154784}}</ref>

==Legality==
AB-PINACA is an [[Drugs controlled by the German Betäubungsmittelgesetz|Anlage II]] controlled substance in Germany as of November 2014.<ref>{{cite web | url=http://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html | title=Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) Anlage II (zu § 1 Abs. 1) (verkehrsfähige, aber nicht verschreibungsfähige Betäubungsmittel) | accessdate=22 June 2015}}</ref>

AB-PINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.<ref>{{cite web | url=http://www.cnb.gov.sg/Libraries/CNB_Newsroom_Files/CNB_NR_-_30_Apr_2015.sflb.ashx | title=CNB NEWS RELEASE | publisher=Central Narcotics Bureau (CNB) | date=30 April 2015 | accessdate=24 July 2015}}</ref>

It's a [[List of Schedule I drugs (US)|Schedule I]] controlled substance in the USA.<ref>{{cite web | url=http://www.gpo.gov/fdsys/pkg/FR-2015-01-30/pdf/2015-01776.pdf | title=Schedules of controlled substances: Temporary placement of three synthetic cannabinoids into schedule I. Final order | publisher=Drug Enforcement Administration, Department of Justice | date=30 January 2015 | accessdate=9 July 2015}}</ref>

As of October 2015 AB-PINACA is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

As of March 2017 AB-PINACA is a controlled substance in France.<ref>{{cite web | url=https://www.legifrance.gouv.fr/eli/arrete/2017/3/31/AFSP1710288A/jo/texte | title=Arrêté du 31 mars 2017 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants 
 | publisher=Legifrance | date=6 April 2017 | language=French | accessdate=6 April 2017}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[5F-AB-PINACA]]
* [[5F-ADB]]
* [[5F-AMB]]
* [[5F-APINACA]]
* [[5F-CUMYL-PINACA]]
* [[AB-CHFUPYCA]]
* [[AB-FUBINACA]]
* [[AB-PICA]]
* [[ADB-CHMINACA]]
* [[ADB-FUBINACA]]
* [[ADB-PINACA]]
* [[ADBICA]]
* [[APICA]]
* [[APINACA]]
* [[MDMB-CHMICA]]
* [[PX-3]]
{{Div col end}}

==References==
<references/>

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Indazoles]]
[[Category:Indazolecarboxamides]]
[[Category:CB1 receptor agonists]]
[[Category:CB2 receptor agonists]]

{{cannabinoid-stub}}